92 related articles for article (PubMed ID: 26266878)
1. Genetic markers of recurrence in colorectal cancer.
Smolle MA; Pichler M; Haybaeck J; Gerger A
Pharmacogenomics; 2015; 16(11):1315-28. PubMed ID: 26266878
[TBL] [Abstract][Full Text] [Related]
2. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
5. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.
Rodrigues D; Longatto-Filho A; Martins SF
Biomed Res Int; 2016; 2016():6896024. PubMed ID: 27563673
[TBL] [Abstract][Full Text] [Related]
6. Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
Lai CY; Sung FC; Hsieh LL; Tang R; Chiou HY; Wu FY; Yeh CC
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S599-606. PubMed ID: 23800895
[TBL] [Abstract][Full Text] [Related]
7. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
8. Important molecular genetic markers of colorectal cancer.
Kudryavtseva AV; Lipatova AV; Zaretsky AR; Moskalev AA; Fedorova MS; Rasskazova AS; Shibukhova GA; Snezhkina AV; Kaprin AD; Alekseev BY; Dmitriev AA; Krasnov GS
Oncotarget; 2016 Aug; 7(33):53959-53983. PubMed ID: 27276710
[TBL] [Abstract][Full Text] [Related]
9. Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer.
Bruun J; Kolberg M; Ahlquist TC; Røyrvik EC; Nome T; Leithe E; Lind GE; Merok MA; Rognum TO; Bjørkøy G; Johansen T; Lindblom A; Sun XF; Svindland A; Liestøl K; Nesbakken A; Skotheim RI; Lothe RA
Clin Cancer Res; 2015 Aug; 21(16):3759-70. PubMed ID: 25910952
[TBL] [Abstract][Full Text] [Related]
10. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of microRNA-21 in colorectal cancer.
Zhao J; Zhang Y; Zhao G
Cancer Biomark; 2015; 15(3):219-26. PubMed ID: 25769454
[TBL] [Abstract][Full Text] [Related]
12. Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.
Benhaim L; Gerger A; Bohanes P; Paez D; Wakatsuki T; Yang D; Labonte MJ; Ning Y; El-Khoueiry R; Loupakis F; Zhang W; Laurent-Puig P; Lenz HJ
Pharmacogenomics J; 2014 Apr; 14(2):135-41. PubMed ID: 23752739
[TBL] [Abstract][Full Text] [Related]
13. MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer.
Christensen LL; Tobiasen H; Holm A; Schepeler T; Ostenfeld MS; Thorsen K; Rasmussen MH; Birkenkamp-Demtroeder K; Sieber OM; Gibbs P; Lubinski J; Lamy P; ; Laurberg S; Oster B; Hansen KQ; Hagemann-Madsen R; Byskov K; Ørntoft TF; Andersen CL
Int J Cancer; 2013 Jul; 133(1):67-78. PubMed ID: 23280316
[TBL] [Abstract][Full Text] [Related]
14. Biomolecular markers as determinants of patients selection for adjuvant chemotherapy of sporadic colorectal cancers.
Sudoyo AW
Acta Med Indones; 2010 Jan; 42(1):45-50. PubMed ID: 20737746
[TBL] [Abstract][Full Text] [Related]
15. High-throughput RNAi screening of human kinases identifies predictors of clinical outcome in colorectal cancer patients treated with oxaliplatin.
Lin M; Zhang Y; Li A; Tang E; Peng J; Tang W; Zhang Y; Lu L; Xiao Y; Wei Q; Yin L; Li H
Oncotarget; 2015 Jun; 6(18):16774-85. PubMed ID: 25904054
[TBL] [Abstract][Full Text] [Related]
16. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
17. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
18. Association between GWAS-identified genetic variations and disease prognosis for patients with colorectal cancer.
Kang BW; Jeon HS; Chae YS; Lee SJ; Park JY; Choi JE; Park JS; Choi GS; Kim JG
PLoS One; 2015; 10(3):e0119649. PubMed ID: 25799222
[TBL] [Abstract][Full Text] [Related]
19. Molecular biomarkers in colorectal carcinoma.
Puerta-García E; Cañadas-Garre M; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(10):1189-222. PubMed ID: 26237292
[TBL] [Abstract][Full Text] [Related]
20. E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer.
Hebbar M; Adenis A; Révillion F; Duhamel A; Romano O; Truant S; Libersa C; Giraud C; Triboulet JP; Pruvot FR; Peyrat JP
Eur J Cancer; 2009 Jul; 45(10):1871-6. PubMed ID: 19361981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
